

CONTENTS

FOREWORD	11
ARGUMENT	13

PART I THE MOLECULAR CHARACTERIZATIONS OF DRUG-TARGET INTERACTIONS

CHAPTER I CELLULAR TESTS: USE AND IMPACT ON MEDICAL DISCOVERY

1.1. Introduction	19
1.2. Membrane proteins and fast cellular responses	24
1.3. Evaluation of gene and protein expression in the high-throughput screening systems	34
1.4. Spatio-temporal cellular reactions and subpopulation analysis	42
1.5. Phenotypic analyses	51

CHAPTER 2 KNOCKOUT GENE INVOLVEMENT IN UNDERSTANDING DISEASE MECHANISMS AND DEVELOPING NEW THERAPEUTIC STRATEGIES

2.1 Introduction	59
2.2. Knockout genes in mice	59
2.3. Tissue-specific gene expression	70
2.4. Transgenic mice	76
2.5. Damage of target genes in <i>Drosophila</i>	78
2.6. Inactivation of target genes in the zebrafish	79
2.7. <i>Caenorhabditis elegans</i> target strain deletion	81

CHAPTER 3
REPORTER GENE-BASED TESTING SYSTEMS
INVESTIGATING G PROTEIN-COUPLED RECEPTORS INVOLVED IN THE
DISCOVERY OF NEW DRUGS

3.1. Receptors and cell communication	83
3.2. Affinity and activity of GPCR ligands	88
3.3. The role of transcription factors in gene expression	89
3.4. Reporter genes	91
3.5. Test systems based on reporter genes for investigating GPCRs	98

CHAPTER 4
FROM HUMAN GENOME TO NEW DRUGS: THE POTENTIAL G PROTEIN-
COUPLED ORPHAN RECEPTORS

4.1. Introduction	105
4.2. GPCRs and the human genome	108
4.3. The investigation of ligands	112
4.4. Screening for oGPCR ligands using functional tests	118
4.5. Prospects	130

PART II
DRUG SYNTHESIS BASED ON ENZYMES AND NUCLEIC ACIDS

CHAPTER 5
STEREOSELECTIVE DRUG SYNTHESIS USING
RECOMBINANT ENZYMES

5.1. Stereoselective synthesis before the advent of genetic engineering	135
5.2. Classical strain improvement methods for stereoselective synthesis	139
5.3. Genetic engineering and the emergence of recombinant enzymes for stereoselective synthesis	140
5.4. β -lactam antibiotics	143
5.5. Polyketide antibiotics	150
5.6. Vitamins	153
5.7. Steroids	159
5.8. Other drugs	160
5.9. Conclusions	163

CHAPTER 6
PHARMACEUTICAL DRUGS BASED ON NUCLEIC ACIDS

6.1. Introduction	165
6.2. The chemical synthesis of oligonucleotides	166
6.3. Chemical oligonucleotide modifications	168
6.4. Mechanism of action	176
6.5. Identification of positioning of sites accessible to ribozymes in the target RNA	187
6.6. Exogenous ribozyme distribution	188
6.7. Oligonucleotide applications in gene expression inhibition	191
6.8. Conclusions	191

PART III
ANALYTICAL METHODS INVOLVED IN THE PRODUCTION AND USE OF DRUGS

CHAPTER 7
RECENT TRENDS IN ENANTIOSEPARATION OF CHIRAL DRUGS

7.1. Introduction	195
7.2. Current status of development and use of chiral drugs	198
7.3. The role of separation technologies in the production, research and use of chiral drugs	200
7.4. Preparation of enantiopure drugs	201
7.5. Chiral drug bioassay	213
7.6. Prospects	224

CHAPTER 8
AFFINITY CHROMATOGRAPHY: APPLICATIONS IN BIOPHARMACEUTICS

8.1. Introduction	225
8.2. The principles of affinity chromatography	226
8.3. Ligand	229
8.4. Affinity matrix	234
8.5. Operating principles	238
8.6. Affinity chromatography models	239
8.7. Applications of affinity interactions	247

CHAPTER 9
NUCLEAR MAGNETIC RESONANCE-BASED
DRUG IDENTIFICATION

9.1. Introduction	259
9.2. Structure-activity relationship (SAR) by NMR	260
9.3. Monitoring of small molecules	270
9.4. Conclusions	281

CHAPTER 10
LABELING PROTEINS WITH ¹³C AND ¹⁵N ISOTOPES FOR ANALYSIS OF THE
STRUCTURE AND DYNAMICS
OF BIOLOGICAL MACROMOLECULES

10.1 Introduction	283
10.2. Expression systems of in vivo incorporation of ¹³ C and ¹⁵ N isotopes into proteins	284
10.3 Cell-free isotopic labeling	297

CHAPTER 11
USE OF ANTIBODY FRAGMENTS AS MEDIATORS IN MEMBRANE PROTEIN
CRYSTALLIZATION TO DISCOVER NEW DRUGS

11.1. Introduction	311
11.2. Crystallization of membrane proteins mediated by antibody fragments	314
11.3. Conclusions	331

PART IV
ELEMENTS OF DRUG KINETICS, METABOLISM AND TOXICOLOGY

CHAPTER 12
PHARMACOGENETICS: EFFECT OF GENETIC VARIATIONS ON DRUG
AVAILABILITY AND RESPONSE

12.1. General considerations	335
12.2. Genotype-phenotype relations	336
12.3. Establishing genotype-phenotype relationships	337
12.4. Phenotyping versus genotyping and individual drug response prediction	339
12.5. Genetic polymorphism of drug-metabolizing enzymes (DMEs)	341
12.6. CYP2D6 polymorphism	246
12.7. The genetic polymorphism of drug transporters	349

12.8. Multiple drug resistance (MDR) gene – marker vs. functional polymorphism	349
12.9. Genetic polymorphism of drug targets	350
12.10. Conclusions	355

CHAPTER 13
DRUG BIOAVAILABILITY AND
CLEARANCE PHARMACOGENOMICS

13.1. Introduction	357
13.2 The contribution of metabolism drugs clearance	358
13.3. Drug transporters: P-glycoprotein (P-gp)	367
13.4. Conclusions	369

CHAPTER 14
TOXICOGENOMICS: INTEGRATING THE NEW METHODS OF MOLECULAR
BIOLOGY INTO TOXICOLOGY

14.1. The development of toxicology	371
14.2. Functional genomics: new technologies of molecular biology	373
14.3. Integrating functional genomic technologies in toxicology	383
14.4. Toxicogenomics applications in studying the mechanism of hepatotoxicity induced by bromobenzene	387
14.5. Conclusions	389

CHAPTER 15
THE IMPORTANCE OF GENETIC POLYMORPHISM
AND DRUG INTERACTIONS
IN THE TREATMENT OF PAIN

15.1. Introduction	391
15.2. Genetic polymorphism: effects on various analgesics	393
15.3. P-gp: another example of genetic variability	404
15.4. Genotyping and phenotyping: prospects	406
15.5. Conclusions	409

REFERENCES	411
------------	-----